Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX versus QDOLO.
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Chlorpheniramine is an antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Adults: 10 mL (hydrocodone polistirex 10 mg/chlorpheniramine polistirex 8 mg) orally every 12 hours; not to exceed 20 mL per day.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
The terminal elimination half-life for hydrocodone from the polistirex formulation is approximately 3.8-4.5 hours in adults, with extended-release properties due to the polistirex complex. For chlorpheniramine polistirex, the half-life is about 20-24 hours, reflecting the prolonged release. These half-lives support twice-daily dosing in the extended-release formulation.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Hydrocodone polistirex and chlorpheniramine polistirex are excreted primarily renally. Hydrocodone and its metabolites are eliminated via kidneys (about 60-70% as unchanged drug and conjugates), with a small amount in feces (<10%). Chlorpheniramine is also predominantly renally excreted (30-50% unchanged, with metabolites). Biliary/fecal excretion accounts for less than 20% of total clearance for both components.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist